| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-01-05 | BMS (USA - NY) Janssen Biotech, a J&J company (USA - NJ) | Opdivo® (nivolumab) and Darzalex®(daratumumab) | multiple myeloma and solid tumors including non-small cell lung cancer, pancreatic cancer, colorectal cancer, triple negative breast cancer and head and neck cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2017-01-05 | Eli Lilly (USA - IN) | restructuring | Restructuring | |||
| 2017-01-05 | Merus (The Netherlands) IRB Barcelona (Spain) | bispecific antibodies targeting the microenvironnement | research | Cancer - Oncology | Research agreement | |
| 2017-01-05 | Takeda Pharmaceutical (Japan) PvP Biologics (USA - WN) | KumaMax | celiac disease | development | Autoimmune diseases - Inflammatory diseases - Digestive diseases | Development agreement |
| 2017-01-04 | Pfizer (USA - NY) Spark Therapeutics (USA - PA) | SPK-FIX | hemophilia B | development |
Hematological diseases - Genetic diseases - Rare diseases | Milestone |
| 2017-01-04 | Affimed (Germany) The University of Texas MD Anderson Cancer Center (USA - TX) | TandAb® technology in combination with natural killer cell (NK) product | development clinical research commercialisation |
Cancer - Oncology | Clinical research agreement | |
| 2017-01-04 | Boehringer Ingelheim (Germany) leadXpro (Switzerland) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2017-01-04 | Akari Therapeutics (USA - NY - UK) | head of clinical development, head of regulatory affairs | nomination | Rare diseases - Inflammatory diseases | Nomination | |
| 2017-01-04 | Noxxon Pharma (Germany) Aptarion biotech (Germany) | Spiegelmers technology | licensing |
Licensing agreement | ||
| 2017-01-04 | Synpromics (UK) GE Healthcare (USA - WI) | customised synthetic promoters | research - R&D | Technology - Services | Research agreement | |
| 2017-01-03 | Soligenix (USA - NJ) Emergent BioSolutions (USA - MD) | production technology for the RiVax™ drug substance protein antigen | exposure to ricin toxin | collaboration |
Collaboration agreement | |
| 2017-01-03 | BioTime (USA - CA) Cell Cure Neurosciences (Israel) | cell therapies manufacturing center | opening of new premises |
Ophtalmological diseases | Opening of new premises | |
| 2017-01-03 | Alnylam Therapeutics (USA - MA) | chief medical officer | nomination | Nomination | ||
| 2017-01-03 | Corvus Pharmaceuticals (USA - CA) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2017-01-03 | Cymabay Therapeutics (USA - CA) Kowa Pharmaceuticals (Japan) | arhalofenate | gout | development licensing commercialisation |
Inflammatory diseases | Development agreement |
| 2017-01-02 | Sanofi Pasteur (France) Merck&Co (USA - NJ) Sanofi Pasteur MSD (SPMSD) | joint-venture |
Infectious diseases | Termination of the agreement | ||
| 2016-12-29 | Medivir (Sweden) Tetralogic Pharmaceuticals Corporation (USA - PA) | remetinostat, birinapant and all intellectual property and data associated with Tetralogic’s HDAC inhibitor and SMAC mimetic projects. | early stage cutaneous T-cell lymphoma, solid tumours, High-grade serous carcinomas | pipeline acquisition | Cancer - Oncology | Pipeline acquisition |
| 2016-12-28 | OSE Immunotherapeutics (France) Servier (France) | Effi-7 | ulcerative colitis, Sjögren syndrome. | development licensing commercialisation |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Development agreement |
| 2016-12-27 | Pluristem Therapeutics (Israel) New York Blood Center (USA - NY) | Placental eXpanded (PLX)-R18 cells | umbilical cord blood transplantation | collaboration |
Transplantation | Collaboration agreement |
| 2016-12-26 | Kubota Pharmaceutical (Japan) SBI Group (Japan) | joint-venture |
Ophtalmological diseases | Joint-venture agreement |
